|Articles|April 21, 2016
FDA's Breakthrough Designation is Working, Says Report
April 21, 2016.
Advertisement
The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .
Read Jill Wechsler's view in
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Capital Flows into Pharma with Funding Rounds and Loan Facilities
2
Beyond Skill-Building: Insights for C-Suite Leaders on Attracting, Developing, and Retaining the Best Possible Workforce
3
Roundup: Biopharmaceutical Industry Activity Accelerates with Focus on Rare Diseases and Novel Therapies
4
The Situation We Faced: The Hard Lessons of Scaling Stem Cell Production
5
